What Has Changed in the Management of Uterine Serous Carcinomas? Two Decades of Experience.


Journal

Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503

Informations de publication

Date de publication:
20 11 2021
Historique:
received: 04 09 2021
revised: 09 11 2021
accepted: 17 11 2021
entrez: 13 12 2021
pubmed: 14 12 2021
medline: 24 3 2022
Statut: epublish

Résumé

Uterine serous carcinoma accounts for 3-10% of endometrial cancers, but it is the most lethal histopathological subtype. The molecular characterization of endometrial carcinomas has allowed novel therapeutic approaches for these patients. We undertook a retrospective analysis of patients with uterine serous carcinomas treated in our hospital within the last two decades to identify possible changes in their management. The patients and their characteristics were evenly distributed across the two decades. Treatment modalities did not change significantly throughout this period. After adjuvant treatment, patients' median disease-free survival was 42.07 months (95% CI: 20.28-63.85), and it did not differ significantly between the two decades (

Identifiants

pubmed: 34898589
pii: curroncol28060410
doi: 10.3390/curroncol28060410
pmc: PMC8628752
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

4862-4873

Références

Virchows Arch. 2013 Mar;462(3):289-96
pubmed: 23417747
Signal Transduct Target Ther. 2020 Jul 29;5(1):137
pubmed: 32728057
J Gynecol Oncol. 2020 Sep;31(5):e64
pubmed: 32808495
Int J Gynecol Cancer. 2008 Nov-Dec;18(6):1344-51
pubmed: 18248390
Ther Adv Med Oncol. 2021 Aug 14;13:17588359211035959
pubmed: 34408794
Nature. 2013 Oct 17;502(7471):333-339
pubmed: 24132290
Expert Rev Anticancer Ther. 2011 Jan;11(1):71-81
pubmed: 21166512
Am J Clin Oncol. 1982 Dec;5(6):649-55
pubmed: 7165009
Int J Gynecol Cancer. 2020 Dec;30(12):2002-2007
pubmed: 33046573
Gynecol Oncol. 2020 Jun;157(3):619-623
pubmed: 32247604
Lancet Oncol. 2019 Sep;20(9):1273-1285
pubmed: 31345626
J Hum Genet. 2021 Sep;66(9):853-868
pubmed: 34092788
Int J Stroke. 2018 Aug;13(6):612-632
pubmed: 29786478
Lancet. 2016 Mar 12;387(10023):1094-1108
pubmed: 26354523
Eur J Cancer. 2020 Jul;133:104-111
pubmed: 32454416
Int J Gynecol Cancer. 2016 Feb;26(2):301-6
pubmed: 26745699
BMC Med Genet. 2019 Dec 21;20(1):202
pubmed: 31864301
Lancet Oncol. 2018 Mar;19(3):295-309
pubmed: 29449189
J Clin Oncol. 2004 Aug 1;22(15):3126-32
pubmed: 15284264
J Clin Oncol. 2020 Sep 10;38(26):2981-2992
pubmed: 32167863
Annu Rev Pathol. 2019 Jan 24;14:339-367
pubmed: 30332563
J Pathol. 2017 Oct;243(2):230-241
pubmed: 28718916
Int J Gynecol Cancer. 2017 Jul;27(6):1293-1297
pubmed: 28604452
Gynecol Oncol. 2009 Oct;115(1):142-153
pubmed: 19592079
Gynecol Oncol. 2003 Dec;91(3):463-9
pubmed: 14675663
Prz Menopauzalny. 2016 Jun;15(2):63-8
pubmed: 27582678
Horm Mol Biol Clin Investig. 2020 Dec 18;42(1):105-111
pubmed: 33781006
Int J Gynecol Cancer. 2017 Jan;27(1):85-92
pubmed: 27759595
Am J Surg Pathol. 2014 Jun;38(6):844-51
pubmed: 24698965
Int J Gynaecol Obstet. 2018 Oct;143 Suppl 2:37-50
pubmed: 30306580
Curr Opin Obstet Gynecol. 2010 Feb;22(1):21-9
pubmed: 19952744
Ann Oncol. 2016 Jan;27(1):16-41
pubmed: 26634381
Cancers (Basel). 2021 May 26;13(11):
pubmed: 34073635
Int J Gynecol Cancer. 2021 Jan;31(1):12-39
pubmed: 33397713
Gynecol Oncol. 2015 Nov;139(2):268-74
pubmed: 26352641
Mod Pathol. 2016 Jan;29 Suppl 1:S45-58
pubmed: 26715173
Gynecol Oncol. 2014 May;133(2):221-8
pubmed: 24556064
Ann Oncol. 2008 May;19 Suppl 2:ii19-20
pubmed: 18456753
Int J Gynecol Cancer. 2020 Aug;30(8):1089-1094
pubmed: 32675056
Crit Rev Oncol Hematol. 2020 Aug;152:102973
pubmed: 32497971
Clin Cancer Res. 2020 Aug 1;26(15):3928-3935
pubmed: 32601075
Int J Gynecol Cancer. 2011 Jul;21(5):877-84
pubmed: 21666484
Nat Rev Clin Oncol. 2011 May;8(5):261-71
pubmed: 21221135
Gynecol Oncol. 2018 Jun;149(3):531-538
pubmed: 29559170
Obstet Gynecol. 2012 Dec;120(6):1371-81
pubmed: 23168762
J Turk Ger Gynecol Assoc. 2018 Mar 1;19(1):23-28
pubmed: 29072180
Arch Pathol Lab Med. 2014 Mar;138(3):343-50
pubmed: 24576030
Gynecol Oncol. 2003 Dec;91(3):470-5
pubmed: 14675664
Arch Gynecol Obstet. 2013 Feb;287(2):351-6
pubmed: 23100038

Auteurs

Michalis Liontos (M)

Department of Clinical Therapeutics, Alexandra Hospital, National and Kapodistrian University of Athens, 11528 Athens, Greece.

Anna Svarna (A)

Department of Clinical Therapeutics, Alexandra Hospital, National and Kapodistrian University of Athens, 11528 Athens, Greece.

Charalampos Theofanakis (C)

1st Department of Obstetrics and Gynecology, Alexandra Hospital, National and Kapodistrian University of Athens, 11528 Athens, Greece.

Oraianthi Fiste (O)

Department of Clinical Therapeutics, Alexandra Hospital, National and Kapodistrian University of Athens, 11528 Athens, Greece.

Angeliki Andrikopoulou (A)

Department of Clinical Therapeutics, Alexandra Hospital, National and Kapodistrian University of Athens, 11528 Athens, Greece.

Maria Kaparelou (M)

Department of Clinical Therapeutics, Alexandra Hospital, National and Kapodistrian University of Athens, 11528 Athens, Greece.

Konstantinos Koutsoukos (K)

Department of Clinical Therapeutics, Alexandra Hospital, National and Kapodistrian University of Athens, 11528 Athens, Greece.

Nikolaos Thomakos (N)

1st Department of Obstetrics and Gynecology, Alexandra Hospital, National and Kapodistrian University of Athens, 11528 Athens, Greece.

Dimitrios Haidopoulos (D)

1st Department of Obstetrics and Gynecology, Alexandra Hospital, National and Kapodistrian University of Athens, 11528 Athens, Greece.

Alexandros Rodolakis (A)

1st Department of Obstetrics and Gynecology, Alexandra Hospital, National and Kapodistrian University of Athens, 11528 Athens, Greece.

Meletios Athanasios Dimopoulos (MA)

Department of Clinical Therapeutics, Alexandra Hospital, National and Kapodistrian University of Athens, 11528 Athens, Greece.

Flora Zagouri (F)

Department of Clinical Therapeutics, Alexandra Hospital, National and Kapodistrian University of Athens, 11528 Athens, Greece.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH